Products for Research Use Only
RegisterLogin

Ibandronate (Sodium Monohydrate)

CAT: 0804-HY-B0515-01Size: 100 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0515-01Size:100 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase) . Ibandronate Sodium Monohydrate can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium Monohydrate inhibits tumor cell proliferation (such as ER+ breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium Monohydrate is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) [1][2][3][4].
CAS Number
138926-19-9
Product Name Alternative
BM-210955; RPR-102289A
UNSPSC
12352211
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/Ibandronate-Sodium-Monohydrate.html
Concentration
10mM
Purity
98.0
Solubility
DMSO : < 1 mg/mL (ultrasonic; warming; heat to 80°C) |H2O : 25 mg/mL (ultrasonic)
Smiles
OC(P(O)(O)=O)(P(O)(O[Na])=O)CCN(C)CCCCC.O
Molecular Formula
C9H24NNaO8P2
Molecular Weight
359.23
Precautions
H302, H315, H319, H335
References & Citations
[1]Journe F, et al. Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines. Breast Cancer Res. 2006;8 (1) :R2.|[2]Thaler R, et al. Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells. Biochem Pharmacol. 2013 Jan 15;85 (2) :173-85.|[3]Pfister T, et al. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology. 2003 Sep 30;191 (2-3) :159-67.|[4]Russell RG. Ibandronate: pharmacology and preclinical studies. Bone. 2006 Apr;38 (4 Suppl 1) :S7-12.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched

Related Products

CatalogName
HY-B0515B-01Ibandronate (Sodium)
HY-128740-01Mesoxalate (sodium) (monohydrate)
HY-B0466-01Cloxacillin (sodium monohydrate)
HY-B0465-01Oxacillin (sodium monohydrate)
HY-B0888-01Sulfacetamide (sodium monohydrate)
HY-14664DFluvastatin (sodium monohydrate)
HY-B0555A-01Nafcillin (sodium monohydrate)
HY-B0465R-01Oxacillin (sodium monohydrate) (Standard)
HY-B0555AR-01Nafcillin (sodium monohydrate) (Standard)
HY-W355001Cholic acid (sodium monohydrate)

Alternative Products

CatalogName
TRC-I120001-50MGIbandronate Sodium Monohydrate
GP8563-1gIbandronate sodium salt monohydrate
BI164527Ibandronate sodium monohydrate - Bio-X TM
B1772-50Ibandronate sodium

Popular Products